Rockefeller Capital Management L.P. Grows Position in Sanofi (NASDAQ:SNY)

Rockefeller Capital Management L.P. boosted its stake in Sanofi (NASDAQ:SNY) by 25.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 360,282 shares of the company’s stock after buying an additional 72,065 shares during the period. Rockefeller Capital Management L.P.’s holdings in Sanofi were worth $20,758,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of SNY. Northwest Investment Counselors LLC acquired a new position in Sanofi during the third quarter worth $29,000. POM Investment Strategies LLC purchased a new position in Sanofi during the 2nd quarter valued at about $25,000. Concord Wealth Partners grew its position in Sanofi by 157.8% in the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after acquiring an additional 363 shares in the last quarter. Arrow Financial Corp purchased a new stake in Sanofi during the second quarter worth about $35,000. Finally, Fortitude Family Office LLC lifted its position in shares of Sanofi by 708.6% during the third quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after purchasing an additional 659 shares in the last quarter. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Stock Down 0.5 %

SNY stock opened at $48.49 on Monday. The company’s 50 day moving average price is $52.80 and its 200 day moving average price is $52.15. The firm has a market capitalization of $123.06 billion, a price-to-earnings ratio of 24.74, a PEG ratio of 1.23 and a beta of 0.61. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Friday, October 25th. The company reported $1.57 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $1.35. The company had revenue of $13.44 billion for the quarter, compared to the consensus estimate of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The company’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.55 EPS. On average, equities research analysts anticipate that Sanofi will post 4.28 EPS for the current fiscal year.

Wall Street Analyst Weigh In

SNY has been the subject of a number of research reports. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.